BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 15542809)

  • 1. Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers.
    Lu C; Soria JC; Tang X; Xu XC; Wang L; Mao L; Lotan R; Kemp B; Bekele BN; Feng L; Hong WK; Khuri FR
    J Clin Oncol; 2004 Nov; 22(22):4575-83. PubMed ID: 15542809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
    Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
    Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patients with nonsmall cell lung carcinoma.
    Fujita Y; Fujikane T; Fujiuchi S; Nishigaki Y; Yamazaki Y; Nagase A; Shimizu T; Ohsaki Y; Kikuchi K
    Cancer; 2003 Sep; 98(5):1008-13. PubMed ID: 12942569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer.
    Wang L; Soria JC; Kemp BL; Liu DD; Mao L; Khuri FR
    Clin Cancer Res; 2002 Sep; 8(9):2883-9. PubMed ID: 12231532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer.
    Metzger R; Vallbohmer D; Müller-Tidow C; Higashi H; Bollschweiler E; Warnecke-Eberz U; Brabender J; Baldus SE; Xi H; Berdel WE; Serve H; Hoelscher AH; Schneider PM
    Anticancer Res; 2009 Apr; 29(4):1157-62. PubMed ID: 19414359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel molecular staging protocol for non-small cell lung cancer.
    Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
    Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
    Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
    Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients.
    Timotheadou E; Skarlos DV; Samantas E; Papadopoulos S; Murray S; Skrickova J; Christodoulou C; Papakostantinou C; Pectasides D; Papakostas P; Kaplanova J; Vrettou E; Karina M; Kosmidis P; Fountzilas G
    Anticancer Res; 2007; 27(6C):4481-9. PubMed ID: 18214064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma.
    Maruyama R; Sugio K; Yoshino I; Maehara Y; Gazdar AF
    Cancer; 2004 Apr; 100(7):1472-7. PubMed ID: 15042681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer.
    Soria JC; Moon C; Kemp BL; Liu DD; Feng L; Tang X; Chang YS; Mao L; Khuri FR
    Clin Cancer Res; 2003 May; 9(5):1785-91. PubMed ID: 12738735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non-small cell lung cancer.
    Hoffmann AC; Kaifi JT; Vallböhmer D; Yekebas E; Grimminger P; Leers JM; Izbicki JR; Hölscher AH; Schneider PM; Metzger R; Brabender J
    J Surg Oncol; 2009 Oct; 100(5):414-7. PubMed ID: 19653236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.
    Gallardo E; Navarro A; Viñolas N; Marrades RM; Diaz T; Gel B; Quera A; Bandres E; Garcia-Foncillas J; Ramirez J; Monzo M
    Carcinogenesis; 2009 Nov; 30(11):1903-9. PubMed ID: 19736307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone.
    Yovino S; Kwok Y; Krasna M; Bangalore M; Suntharalingam M
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1438-43. PubMed ID: 16029805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of MDA-7/IL-24 and its clinical significance in resected non-small cell lung cancer.
    Ishikawa S; Nakagawa T; Miyahara R; Kawano Y; Takenaka K; Yanagihara K; Otake Y; Katakura H; Wada H; Tanaka F
    Clin Cancer Res; 2005 Feb; 11(3):1198-202. PubMed ID: 15709189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CK19 mRNA expression measured by reverse-transcription polymerase chain reaction (RT-PCR) in the peripheral blood of patients with non-small cell lung cancer treated by chemo-radiation: an independent prognostic factor.
    Chen TF; Jiang GL; Fu XL; Wang LJ; Qian H; Wu KL; Zhao S
    Lung Cancer; 2007 Apr; 56(1):105-14. PubMed ID: 17166620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer.
    Zhu ZH; Sun BY; Ma Y; Shao JY; Long H; Zhang X; Fu JH; Zhang LJ; Su XD; Wu QL; Ling P; Chen M; Xie ZM; Hu Y; Rong TH
    J Clin Oncol; 2009 Mar; 27(7):1091-9. PubMed ID: 19188679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of pigment epithelial derived factor is reduced in non-small cell lung cancer and is linked to clinical outcome.
    Zhang L; Chen J; Ke Y; Mansel RE; Jiang WG
    Int J Mol Med; 2006 May; 17(5):937-44. PubMed ID: 16596284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
    Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Retinoid expression (RARbeta and CRBP1) in non-small-cell lung carcinoma].
    Mauro LV; Dalurzo M; Smith D; Lastiri J; Vasallo B; Joffei EB; Pallotta MG; Puricelli L
    Medicina (B Aires); 2008; 68(3):205-12. PubMed ID: 18689151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.